Lapatinib - CAS 231277-92-2
Catalog number: 231277-92-2
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C29H26ClFN4O4S
Molecular Weight:
581.06
COA:
Inquire
Targets:
EGFR
Description:
Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
GW-572016, GSK572016
MSDS:
Inquire
1.A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
Brian Thiessen • Clinton Stewart • Ming Tsao • Suzanne Kamel-Reid. Cancer Chemother Pharmacol (2010) 65:353–361
We were unable to demonstrate any beneWt of lapatinib in the 17 patients enrolled in the phase II arm of this trial. Only four patients demonstrated stable disease and 13 patients showed early progression, thus, even in the absence of response, there was no signal of activity in terms of delay in progression in meaningful numbers of patients. Because of these results, as per protocol, the phase II portion of the trial was closed to accrual. At that time, seven patients had been enrolled into the phase I arm of the trial and although a recommended dose had not been identiWed, the lack of eYcacy of the agent made the pursuit of a recommended dose in this population no longer relevant. In both EIAED and non-EIAED patients, we were able to con- Wrm that lapatinib was a well tolerated agent. No Grade 4 toxicities were seen and no cardiac toxicity was identiWed. There are several possible reasons for the lack of eYcacy in this tumor group. Lapatinib may perform better in cells that have both ErB-1 and ErbB-2 expression rather than isolated ErbB-1 overexpression. In fact, lapatinib may bind only to inactive/intermediate form of EGFR and constitutively active EGFR (i.e., EGFRvIII mutation) may not be inhibited at all.
2.Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
Thomas E. Delea • Paul Tappenden • Oleg Sofrygin • Dominy Browning. Eur J Health Econ (2012) 13:589–603
EGF100151 was a phase III randomized controlled trial to evaluate the efficacy and safety of combined therapy with lapatinib, an orally administered dual inhibitor of ErbB1 and HER2, plus capecitabine versus capecitabine monotherapy in women with HER2-positive metastatic breast cancer previously treated with an anthracycline and a taxane (for adjuvant and/or metastatic disease) and trastuzumab (for metastatic disease) [10]. Patients in the combination therapy arm received lapatinib 1,250 mg daily continuously plus capecitabine 2,000 mg/m2 daily for 14 days every 3 weeks. Those in the capecitabine monotherapy arm received capecitabine 2,500 mg/m2 daily for 14 days every 3 weeks. Approximately one-half of subjects had received C4 prior lines of chemotherapy prior to randomization. Based on the recommendation of an independent data-monitoring committee reviewing data up to 15 November 2005, enrolment into the trial was discontinued and crossover to lapatinib plus capecitabine was offered to women receiving capecitabine monotherapy as of 3 April 2006.
3.Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
John P. Crown, Harold A. Burris III, Fran Boyle , Suzanne Jones, Maria Koehler. Breast Cancer Res Treat (2008) 112:317–325
Lapatinib (Tykerb®/Tyverb®; GlaxoSmithKline, Philadelphia, PA) is an oral, dual tyrosine kinase inhibitor targeting both EGFR (ErbB1) and HER2 (ErbB2) receptors. Lapatinib is approved in the United States, Switzerland, Australia, and several other international markets for the treatment of advanced or metastatic breast cancer in patients with HER2-positive tumors who have progressed on treatment regimens containing an anthracycline, a taxane, and trastuzumab. Lapatinib is clinically active as a single agent or in combination with various chemotherapy agents in patients with HER2-positive breast cancer and other solid tumors.
4.Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
Nancy U. Lin • Wolfgang Eierman • Richard Greil • Mario Campone. J Neurooncol (2011) 105:613–620
Lapatinib is an orally bioavailable, 4-aniloquinazoline tyrosine kinase inhibitor of the epidermal growth factor and HER2. In animal models, lapatinib inhibits CNS outgrowth of HER2-positive cell lines. CNS therapeutic levels have been demonstrated in tumor resection specimens in patients with glioblastoma multiforme. Two phase 2 trials have evaluated lapatinib monotherapy in patients with progressive HER2-positive, brain metastases.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products


AZ5104
(CAS: 1421373-98-9)

AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of

EGF816
(CAS: 1508250-71-2)

EGF816, also called as Nazartinib, a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M resistance mutation while sparing wild-type EGFR. ...

CAS 257933-82-7 Pelitinib

Pelitinib
(CAS: 257933-82-7)

Pelitinib is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity. EKB-569 irreversibly binds covalently to epidermal gr...

Naquotinib
(CAS: 1448232-80-1)

Naquotinib is a irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activitywith ...

CAS 1213269-23-8 WZ-4002

WZ-4002
(CAS: 1213269-23-8)

CAS 845272-21-1 Varlitinib

Varlitinib
(CAS: 845272-21-1)

Varlitinib, also known as ARRY-543, is an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. V...

PF-06747775
(CAS: 1776112-90-3)

PF-06747775, a methylpurin derivative, has been found to be an epidermal growth factor receptor antagonist and could probably be effective against cell lung can...

PF-06459988
(CAS: 1428774-45-1)

PF-06459988 is a third-generation, irreversible epidermal growth factor receptor (EGFR) inhibitor. It can bind to and inhibit mutant forms of EGFR, including th...

CAS 451493-31-5 AV-412 Tosylate

AV-412 Tosylate
(CAS: 451493-31-5)

AV-412 is a dual EGFR/ErbB2 kinase inhibitor. It completely inhibits the tumor growth of both H1650 and H1975 xenografts in nude mice. It is proved that AV-412 ...

CAS 153436-54-5 PD-153035

PD-153035
(CAS: 153436-54-5)

PD153035 is a ATP-competitive EGFR inhibitor with an IC50 and Ki of 25 and 6 pM. PD153035 effectively blocks the enhancement of mitogenesis, induction of early ...

CAS 1421373-65-0 AZD-9291

AZD-9291
(CAS: 1421373-65-0)

AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...

BGB-283
(CAS: 1446090-77-2)

BGB-283 is a selective Epidermal growth factor receptor and Proto oncogene protein b raf inhibitor under the development of BeiGene. BGB-283 shows antitumor act...

CAS 383432-38-0 CP-724714

CP-724714
(CAS: 383432-38-0)

CP-724714 is An orally bioavailable quinazoline with potential antineoplastic activity. CP-724,714 selectively binds to the intracellular domain of HER2, revers...

CAS 850140-73-7 Afatinib Dimaleate

Afatinib Dimaleate
(CAS: 850140-73-7)

Afatinib Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, res...

CAS 451492-95-8 MP-412

MP-412
(CAS: 451492-95-8)

MP-412 (AV-412) is a second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to an...

CAS 848942-61-0 AZD-8931

AZD-8931
(CAS: 848942-61-0)

Sapitinib, also known as AZD-8931, is an erbB receptor tyrosine kinase inhibitor with potential antineoplastic activity. AZD8931 binds to and inhibits erbB tyro...

CO-1686 hydrobromide
(CAS: 1446700-26-0)

CO-1686 hydrobromide is the hydrobromide salt form of CO-1686. CO-1686, also called as Rociletinib, is an oral tyrosine kinase inhibitor that irreversibly and s...

CAS 1374640-70-6 CO1686

CO1686
(CAS: 1374640-70-6)

Naquotinib mesylate
(CAS: 1448237-05-5)

Naquotinib is irreversible, third-generation, epidermal growth factor receptor (EGFR) inhibitor with IC50 value of 70 nM for NCI-H1650 cell growth. It can coval...

Tarloxotinib bromide
(CAS: 1636180-98-7)

Tarloxotinib bromide, a pyridopyrimidine derivative, has been found to be a EGFR tyrosine kinase inhibitor precursor and could probably be effective in antineop...

Chemical Structure

CAS 231277-92-2 Lapatinib

Quick Inquiry

Verification code

Featured Items